Evaluation of a New Emergency Department Avoidance Model of Care, the Cancer Urgent Assessment Clinic, in Response to the COVID-19 Pandemic
Overview
Affiliations
Introduction: The Cancer Urgent Assessment Clinic (CUAC) was an emergency department (ED) avoidance/unscheduled model of care implemented in response to the COVID-19 pandemic. The aim was to reduce the risk of COVID-19 exposure and infection by providing an alternative to ED for cancer patients while undergoing anticancer treatments.
Methods: The clinic incorporated a telephone triage process and face-to-face appointments 8am to 8pm, 7 days per week. CUAC operated between 23 March '20 and 31 July '20, led by a nurse practitioner candidate, oncology registrars, cancer nurse specialists, and overseen by oncology consultants. Evaluation followed a mixed-methods approach through (1) analysis of CUAC patient data, (2) comparison of ED cancer patient presentation data from a previous period (23 March 2019-31 July 2019), and (3) a patient survey.
Results: In total, 400 patients were telephone triaged via CUAC, with 166 recorded as having avoided ED. There was a reduction in the number of cancer patient admissions to the ED short stay unit during the clinic period compared with the same time-period in 2019: 130 vs. 234, associated with 615 fewer hours. Patient satisfaction was positive particularly regarding ease of access, time to treatment, confidence in assessment and treatment of cancer-related concerns, and likelihood of presenting to hospital when unwell during the pandemic.
Discussion: While initially being implemented to reduce the risk of COVID-19 exposure, this evaluation demonstrated the CUAC model was an efficient and potentially cost-saving model of care for the management of cancer patients with mild to moderate severity of disease and treatment-related concerns.
M Chess-Williams L, M Broadbent A, Hattingh L BMC Palliat Care. 2024; 23(1):172.
PMID: 39010021 PMC: 11251105. DOI: 10.1186/s12904-024-01508-1.
Kulkarni S, Knight T, Cooksley T, Marshall E, Patel N, Selvaratnam R Clin Med (Lond). 2023; 23(6):571-581.
PMID: 38065597 PMC: 11046619. DOI: 10.7861/clinmed.2023-0251.
Hattingh H, Edmunds C, Buksh S, Cronin S, Gillespie B Pharmacy (Basel). 2023; 11(5).
PMID: 37888502 PMC: 10610024. DOI: 10.3390/pharmacy11050157.
Hattingh H, Edmunds C, Gillespie B J Pharm Policy Pract. 2023; 16(1):127.
PMID: 37880768 PMC: 10598939. DOI: 10.1186/s40545-023-00633-1.
Galloway K, Lambert P, Bow E, Czaykowski P, Fatoye T, Goldenberg B Curr Oncol. 2023; 30(7):6771-6785.
PMID: 37504356 PMC: 10378500. DOI: 10.3390/curroncol30070496.